Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 9
Submit an article Journal homepage
151
Views
52
CrossRef citations to date
0
Altmetric
Research Article

Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma

S.L. Chua Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
,
J.F. Seymour Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
,
J. Streater Department of Pharmacy, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
,
M.M. Wolf Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
,
E.H. Januszewicz Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
&
H.M. Prince Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, St. Andrews Place, East Melbourne, Vic. 8006, Australia
Pages 1783-1788 | Published online: 01 Jul 2009

  • van Besien, K,. Ha, CS., Murphy, S., et aI., (1998) -Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.". Blood 91. 1178-1184.
  • Hallender, A., Kvaloy, S., I. me, K., Nome, O. and Holle, H. (2000) "Prognostic (actors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single center analysis". Eur. J, Cancer 36, 1762-1768.
  • Bos, G.M.J., van Pullen, W.L.J., van der Holt, B., el al. 11999) "for which patients with aggressive non-Hodgkin's Iymphoma is prophylaxis for central nervous system disease mandatory?". Aim. Oncol. 9. 191-194.
  • Magrath, I.T. (1997) '-Small noncleaved cell lymphomas (Burkitt's and Burkitt-like lymphomas)". In: Magrath, I.T., ed. The NonHodgkin's Lymphomas. 2nd Ed. (Arnold. London), pp 781 -811.
  • Sandlund, J.T. and Magrath, I.T. 11997) "Lyrnphublastic: Iymphoma". In: Magrath, I.T., ed. The Non-Hodgkin's Lymphomas. 2nd Ed. (Arnold. London), pp 8I3-828.
  • Perez-Soler, R., Smith, T.L. and Cabanillas. E (1986) "Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologie type". Cancer 57.971-977.
  • Grossman, S.A. and Krabak, M.J. (1999) "leptomeningeal carcinomatosis". Cancer Treat. Rev. 25. 103-119.
  • Haioun, C., Besson, C., Lepage, E., et al. (2000) "Incidence and risk factors of central nervous system relapse in hislologicully aggressive nun-Hodgkin"s Iymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients". Aim. Oncol. 11. 685-690.
  • Bollen, E.L., Brouwer, R.E., Hamers, S., et. al., (1997) "Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients". Arch. Neurol. 54, 854-859.
  • Recht, I., Straus, D.J., Cirrincione. (.',. Thaler, H.T. and Posner, J.B. (1998) "Central nervous system melastases from non-Hodgkin's lymphoma: treatment and prophylaxis". Am, J. Med. 84,425-445.
  • Bashir, R.M., Biennan. PJ., Vosc, J.M., Weisenburger, D.D. and Annilage, J.O. (1990 "Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma". Am, J. Clin. Oncol. 14.478-482.
  • Liang, R., Chiu, E. and Luke, S.L. (1990) "Secondary central nervous system involvement by non-Modgkin's lympboma: the risk factors", Hematol. Oncol. 8. 141-145.
  • Young, R.C., Howser, D.M., Andersen, T., Fisher, R.I., Jaffe,E and DeVita. Jr., V.T. 11979) "Central nervous system complications of non-Hodgkin's lymphoma. The potential role tor prophylactic therapy". Am, J. Med, M. 435-443.
  • Litam, J.P., Cabanillas, K, Smith, T.L., Bodey, C.P. and Freireich, EJ. (1979) "Central nervous system relapse in malignuni lymphomas: risk factors ami implications for prophylaxis". Blood 54. 1249-1257.
  • Keldsen, N., Michalski, W., Bentzen. SM, Hansen, K.B. and Thorling, K. (1996) "Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis". Arata Omcol). 35. 703-708.
  • Tomita, N., Kodama, F. Sakal, R., et al., (2000) "Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations". Leuk. lymphoma 38. 335-343.
  • Shahab, N. and Dull, D.C. (1999) "Testicular lymphoma". Scmin. Oncol. 26. 259-269.
  • Hausdorff, J., Devis, E., Long, G., et al., (1997) -Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy". Cancer J. Sci. Am. 3.,303-311.
  • Anonymous (1982) "National cancer institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description ot" a working formulation for clinical usage. The NonHodgkin's Lymphoma Pathologic Classification Project", Cancer 49.2112-2135.
  • The International Non-Hodgkin's Lyinphoma Prognostic Factors Project(1993) "A predictive model for aggressive non-Hodgkin's lymphoma". New Engl, J. Med. 329. 987 -994.
  • Magrath,I.T., Janus.C., Edwards, U.K., et al.,(1984)"An effective therapy for both undifferentiated (including Burkiti's) lymphomas and lymphoblastic lymphomas in children and young adults", Blood 63.1102-1111.
  • Magrath, I., Adde, M., Shad, A., et al., (1996) "Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen", J. Clin. Oncol 14. 925-934.
  • Kanurjian, H.M., O'Brien. S,.Smith, T.L., et.al (2000)-Results of treatment with Hyper-CVAD. u dove intensive regimen, in adult acute lymphobtastic leukemia". J Clin. Oncol. 18. 547-561.
  • Linassier, C., Desablens, B., Tabuteau, S., a at., (2000) "Primary testicular non-lympboblastic intermediate- to high-grade nonHodgkin's lymphoma: results of u prospective Study of the GOELAMS study group". Ann. Oncol. 11(Suppl. 4). 105.
  • Ozsahin, M., Weber, D., Ketterer, N., et al., (2000) -Outcome and patterns of failure in testicular lymphoma: a multicentcr Rare Cancer Network study". Int, J. Radiai, Oncol. Biol. Phys. 48(Suppl.). 216. Abstract #209.
  • Lippuner.T.,Gospodaruwiz, M., Pintilie. M. Slurgeon, J., Tsang, R. and Zanke, B. (1999) "Testicular lymphomas: pattern of failure after longterm folIowup". Ann. Oncol. 19(Suppl. 3). 68.
  • Shapiro, W.R., Young, D.F. and Mehta, B.M. (1975) "Metholrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections", N. Engl, J. Med. 293. 161 -166.
  • Cortes, J., O'Brien, S.M., Pierce, S., Keating. MJ., Freireich, E.J. ami Kuntarjian, H.M. (1995) The value of high-dose systemic chemotherapy and inttathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic letikcmia", Blood 86. 2091 -2097.
  • Blasherg, R.G., Pathak, C. and Fenstermacher, I.D. (1975) "lntrathecal chemotherapy: brain tissue profiles after ventriculocisiernal perfusion", J. Pharmacol. Exp. Ther. 195. 73-83.
  • Glantz, M.J., Cole, B.F., Recht, L., et al., (1998) "High-dose intravenous methotrexate for patients with nonlenkemic leptomeningeal cancer is mirathecal chemotherapy necessary?".,J. Clin. Oncol. 16.1561-1567.
  • Dukic, S., Heunaux, T., Kaltenbaeh, M.L., el al. (1999) "Pharmacokinetics of methurrexate in the extracellular fluid of brain C6-gliuma after intravenou.s infusion in rats". Pharm. Res. 16. 1219-1225.
  • Tetef, M.L. Margolin, K.A., Doroshow, J.H., ti at., (2000)··Pharniat-okinetics and toxicity ot high-dose intravenous inethntrexatc in the treatment of leptomenungeal eareinomatosis", Cancer Chemother. Pharmacol. 46. 19-26.
  • Skarin, A.T., Canellos, G.P., Rosenthal, D.S., et al., (1983)'Improved prognosis of diffuse histineytic and undifferentiated lymphoma by use of high dose methotrexate. alternating with standard agents (M-BACODl'. J Clin. Oncol. 1. 91-98.
  • Moreno, A., Colon-Otero, G. and Solberg, Jr., LA. (2000) -The prednisone dosage in the CHOP chemotherapy regunen for nonHodgkin's lymphomas (NHL): is there a standard?'. Oncologist S. 238-249.
  • Balis, F.M., Lester, C.M., Chrousos, G.P., Heideman, R.L. and Poplack, D.G. (1987) "Differences in cerebrospinal fluid penetration of curticosteroids: possible relationship to the prevention of meningeal leukemia".J Clin. Oncol. 5. 202-207.
  • Jones, B., Freeman, A.I., Shinier, J.J., et al., (1991) "Lower incidence of meningt-al leukemia when prednisonc is replaced by dexaineihaione in the treatment of acute lymphocytic leukemia". Med. Pediar. Oncol. 19. 269-275.
  • Tilly, H. Mounter, N., Lederiin, P., el a!., (2000) "Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: (he LN[187] study. Groupe d'Etudes des Lymphomes de I Adulte", J. Clin. Oncol. 18. 1309-1315.
  • Fisher, R.I., Gaynor, E.R., Dahlberg, S., ft al., (I993)"Comparison of a standard regimen (CHOP) with three intensive ehemotherpy regimens tor advanced non-Hodgkin's lymphoma", N. Engl, J. Med.1002-1006.
  • Grordon, L.I., Flarrington, D., Andersen. J-. et al., (1992) "Comparison of a second-generation combination cheitmtlierapeulic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma". N-. Engl, J. Mrd. 327. 1342-1356.
  • Seymour, J.F., Solomon, B., Wolf, M.M., Janus/ewicz, E.H., Wirth, A. and Prince, H.M. «2001) "Primary large-cell nonHixljjkin's lymphoma of the tcsiis: a rcinispective analysis yf patterns of failure and prognostic factors". Om. Ixmphnma I. 109-115.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.